
|Articles|January 1, 2004
HIFU may offer advantages in PCa, but the jury is still out
Author(s)Michael O. Koch, MD
Over the last 20 years, radical retropubic prostatectomy has evolvedto become the standard of care in men with localized prostate cancer. Becauseof the morbidity of this procedure, however, interest has grown in the developmentof non-surgical modalities. Unfortunately, many of these non-surgical approaches,such as monotherapy with radioactive seed implantation, have resulted indisappointing results or excessive morbidity, as in first-generation cryotherapy.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Elizabeth Nally, MBBS, on decision regret and toxicity perception with adjuvant pembrolizumab
2
Neil Baum, MD, and Abraham Morgentaler, MD, discuss the history of testosterone and prostate cancer
3
Optimizing care for men with overactive bladder, with Keith Xavier, MD
4
The UroOnc Minute: Navigating BCG Maintenance Therapy in NMIBC, With Mark D. Tyson, II, MD, MPH
5






